Table 1.
Patient Characteristics
| ANZ-100 | ID | Age Sex | Cancer Type | Dose Level (cfu) | ECOG PS | Prior Therapies | Mesotheli n IHC | No. Doses |
|---|---|---|---|---|---|---|---|---|
| 01-002 | 57 F | Pancreatic | 10^6 | 0 | 2 | NA | 1 | |
| 02-003 | 53 M | Colorectal | 10^6 | 0 | 2 | NA | 1 | |
| 02-006 | 69 M | Colorectal | 10^6 | 1 | 5 | NA | 1 | |
|
| ||||||||
| 01-005 | 62 M | Pancreatic | 3×10^7 | 0 | 2 | NA | 1 | |
| 02-054 | 66 M | Melanoma | 3×10^7 | 0 | 4 | NA | 1 | |
| 02-058 | 71 M | Colorectal | 3×10^7 | 0 | 4 | NA | 1 | |
|
| ||||||||
| 01-008 | 49 F | Colorectal | 3×10^8 | 0 | 4 | NA | 1 | |
| 02-062 | 57 M | Colorectal | 3×10^8 | 0 | 5 | NA | 1 | |
| 02-064 | 60 M | Colorectal | 3×10^8 | 0 | 5 | NA | 1 | |
| CRS-207 | ID | Age Sex | Cancer Type | Dose Level (cfu) | ECOG PS | Prior Therapies | Mesotheli nIHC | No. Doses |
|---|---|---|---|---|---|---|---|---|
| 001-001 | 65 M | Pancreatic | 10^8 | 0 | 5 | 50%, 2–3+ | 4 | |
| 001-002 | 61 F | Pancreatic | 10^8 | 0 | 4 | NE | 4 | |
| 003-001 | 65 F | Meso | 10^8 | 0 | 2 | 25%, 1–2+ | 4 | |
| 002-001 | 64F | Ovarian | 10^8 | 1 | 8 | NE | 2 | |
| 002-002 | 60 M | Meso | 10^8 | 1 | 1 | NE | 2 | |
| 004-001 | 55 M | Meso | 10^8 | 0 | 4 | NE | 3 | |
|
| ||||||||
| 005-002 | 56 F | NSCLC | 3×10^8 | 0 | 4 | 70%, 2–3+ | 1 | |
| 001-004 | 68 F | Pancreatic | 3×10^8 | 0 | 1 | NE | 3 | |
| 001-005 | 60 M | Pancreatic | 3×10^8 | 1 | 1 | 75%, 2–3+ | 2 | |
| 005-003 | 79 F | Pancreatic | 3×10^8 | 0 | 0 | 80%, 2–3+ | 2 | |
|
| ||||||||
| 004-002 | 59 M | Pancreatic | 10^9 | 1 | 4 | NE | 4 | |
| 005-001 | 56 F | NSCLC | 10^9 | 0 | 5 | 50%, 2+ | 4 | |
| 001-003 | 61 M | Pancreatic | 10^9 | 0 | 2 | NE | 4 | |
| 002-003 | 72 F | NSCLC | 10^9 | 1 | 5 | 100%, 3+ | 4 | |
| 002-004 | 75 M | Meso | 10^9 | 1 | 4 | NE | 2 | |
| 003-002 | 52 F | Ovarian | 10^9 | 1 | 10 | NE | 4 | |
|
| ||||||||
| 003-003 | 40 M | Meso | 10^10 | 1 | 2 | NE | 1 | |
Abbreviations: cfu, colony forming unit; ECOG, Eastern Cooperative Oncology Group; PS, Performance Status; NA, Not Applicable; Meso, mesothelioma, NSCLC, non-small-cell lung cancer; NE, Not Evaluable Mesothelin IHC: The percentage of tumor cells showing membranous staining were evaluated for intensity (0 – no staining; 1+ - weak staining; 2+ - moderate staining; 3+ - strong staining)